New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Data suggest that the current American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging criteria merit further evaluation. We sought to identify and validate factors as enhanced descriptors of STS clinical behavior.
Prospectively accrued data were analyzed for 1,091 AJCC stage I to III primary STS patients who had complete macroscopic resection at our institution from 1996 to 2007. Study factors were examined by univariable and multivariable analyses to identify independent prognostic factors for disease related mortality and overall survival (OS).
In contrast to the current AJCC STS staging system, which stratifies size into T1 (≤5 cm) and T2 (>5 cm) groups, we demonstrated three distinct cohorts (P < 0.0001): T1 (≤5 cm; 5-year OS 85%), T2 (5 to 15 cm; OS 68%), and T3 (>15 cm; OS 52%). A two-category system of histologic grade was demonstrably as informative as the current four histologic grade AJCC system. A multivariable Cox proportional hazard model identified tumor size (5 to 15 cm vs. ≤5 cm, P = 0.03; or >15 cm vs. ≤5 cm; P < 0.0001), nonextremity primary site (P = 0.0016), disease of high histologic grade (P = 0.001), specific histology (P = 0.001), and margin positivity (P < 0.0001) as statistically significant adverse independent prognostic factors. Recurrence during follow-up was the most significant risk factor for STS-specific mortality (P < 0.0001).
Tumor size and grade in the AJCC STS staging system need revision; moreover, primary site, histologic subtype, margin status, and recurrence offer additional relevant prognostic insight. Incorporation of these factors may enhance the AJCC staging system, thereby further facilitating individualized therapeutic strategies for STS patients.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006; 56:106–30. CrossRef
- Lahat G, Lazar AJ, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Oncol Clin N Am (in press)
- Fletcher CD, Unni KK, Mertens F. (2002) World Health Organization classification of tumors. Pathology and genetics. Tumors of soft tissue and bone. Lyon: IARC Press.
- Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701–11. CrossRef
- Brennan MF. Staging of soft tissue sarcomas. Ann Surg Oncol 1999; 6:8–9. CrossRef
- Collin C, Godbold J, Hajdu S, et al. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. Ann Surg Oncol 1987; 5:601–12.
- Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992; 10:1317–29.
- Heise HW, Myers MH, Russell WO, et al. Recurrence-free survival time for surgically treated soft tissue sarcoma patients. Multivariate analysis of five prognostic factors. Cancer 1986; 57:172–7. CrossRef
- Rooser B, Attewell R, Berg NO, et al. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 1988; 61:817–23. CrossRef
- Rydholm A, Berg NO, Gullberg B, et al. Prognosis for soft-tissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients. Acta Pathol Microbiol Immunol Scand 1984; 92:375–86.
- Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219:165–73. CrossRef
- Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33:37–42. CrossRef
- Ueda T, Aozasa K, Tsujimoto M, et al. Multivariate analysis for clinical prognostic factors in 163 patients with soft tissue sarcoma. Cancer 1988; 62:1444–50. CrossRef
- Stotter AT, A’Hern RP, Fisher C, et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65:1119–29. CrossRef
- Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679–89.
- Ramanathan RC, A’Hern R, Fisher C, et al. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 1999; 6:57–69. CrossRef
- Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 2002; 20:4344–52. CrossRef
- Stojadinovic A, Leung DH, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002; 235:424–34. CrossRef
- Stefanovski PD, Bidoli E, De Paoli A, et al. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 2002; 28:153–64. CrossRef
- Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57:739–47.
- Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97:2530–43. CrossRef
- Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003; 237:218–26. CrossRef
- Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:791–6. CrossRef
- Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004; 101:2270–5. CrossRef
- Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004; 426:129–34. CrossRef
- Behranwala KA, A’Hern R, Omar AM, et al. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004; 11:714–9. CrossRef
- Blazer DG 3rd, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol 2003; 12:201–6. CrossRef
- Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459–65. CrossRef
- Kaplan EL, Meier MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:448–57. CrossRef
- Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18:695–706. CrossRef
- Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004; 74:69–75. CrossRef
- Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141–54. CrossRef
- Gray B. Cmprsk: subdistribution analysis of competing risks. Version 2.1-7. Available at: http://cran.r-project.org/web/packages/cmprsk/index.html. Accessed May 16, 2008
- The Mianalyze procedure. SAS onlineDocTM. Chapter 10. Version 8. Available at: http://support.sas.com/rnd/app/papers/mianalyzev802.pdf. Accessed May 16, 2008
- Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484–91. CrossRef
- Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977; 40:1562–70. CrossRef
- Fleming ID, Cooper JS, Henson DE. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
- Greene FL, Page DL, Fleming ID. (2002) AJCC Cancer Staging Manual. 6th edn. New York: Springer.
- Costa J, Wesley RA, Glatstein E, et al. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53:530–41. CrossRef
- Rubin BP, Fletcher CD, Inwards C, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006; 130:1616–29.
- Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007; 141:105–14. CrossRef
- Pisters PWT, Brennan MF. (1995) Sarcomas of soft tissue. In: Abeloff MAJ, Lichter A, et al. (ed) Clinical oncology. New York: Churchill Livingstone. pp 1799–832
- Devita VT, Rosenberg SASH. (2004) Cancer: Principles and practice of oncology. 7th edn. Philadelphia: Lippincott.
- ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, et al. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol 2007; 14:222–9. CrossRef
- Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2007; 109:2522–31. CrossRef
- Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005; 23:96–104. CrossRef
- Packeisen J, Korsching E, Herbst H, et al. Demystified...tissue microarray technology. Mol Pathol 2003; 56:198–204. CrossRef
- New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma
Annals of Surgical Oncology
Volume 15, Issue 10 , pp 2739-2748
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Soft tissue sarcoma
- Prognostic factors
- Industry Sectors
- Author Affiliations
- 1. Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe St., Unit 1104, Houston, TX, 77030, USA
- 2. Sarcoma Research Center, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- 3. Division of Quantitative Sciences, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- 4. Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- 5. Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- 6. Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA